Iranian Journal of Pediatrics

Published by: Kowsar

High-Dose Oral Ibuprofen in Treatment of Patent Ductus Arteriosus in Full-Term Neonates

Shahnaz Pourarian 1 , Mehrdad Rezaie 1 , Hamid Amoozgar 2 , * , Ali-Mohammad Shakiba 2 , Mohammad-Reza Edraki 2 and Nima Mehdizadegan 2
Authors Information
1 Department of Pediatrics, Neonatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Cardiac and Neonatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Iranian Journal of Pediatrics: August 28, 2015, 25 (4); e2005
  • Published Online: August 24, 2015
  • Article Type: Research Article
  • Received: April 16, 2015
  • Accepted: April 27, 2015
  • DOI: 10.5812/ijp.2005

To Cite: Pourarian S, Rezaie M, Amoozgar H, Shakiba A, Edraki M, et al. High-Dose Oral Ibuprofen in Treatment of Patent Ductus Arteriosus in Full-Term Neonates, Iran J Pediatr. 2015 ; 25(4):e2005. doi: 10.5812/ijp.2005.

Copyright © 2015, Growth & Development Research Center.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Allen HD, Driscoll DJ, Shaddy RE, Feltes T. Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. 2007;
  • 2. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998; 50(1): 35-58[PubMed]
  • 3. Thebaud B, Michelakis ED, Wu XC, Moudgil R, Kuzyk M, Dyck JR, et al. Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. Circulation. 2004; 110(11): 1372-9[DOI][PubMed]
  • 4. Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med. 2002; 8(2): 91-2[DOI][PubMed]
  • 5. Loftin CD, Trivedi DB, Langenbach R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest. 2002; 110(4): 549-57[DOI][PubMed]
  • 6. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature. 1997; 390(6655): 78-81[DOI][PubMed]
  • 7. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun. 1998; 246(1): 7-12[DOI][PubMed]
  • 8. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002; 39(12): 1890-900[PubMed]
  • 9. Mullins CE. The Science and Practice of Pediatric Cardiology. 1990; : 1055–6
  • 10. Milliken JC, D'Souza G. Patent Ductus Arteriosus. Review Article eMedicine cardiology. 2007; 115(8): 1039-50
  • 11. Madan JC, Kendrick D, Hagadorn JI, Frantz I3, National Institute of Child H, Human Development Neonatal Research N. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics. 2009; 123(2): 674-81[DOI][PubMed]
  • 12. Benjamin JR, Smith PB, Cotten CM, Jaggers J, Goldstein RF, Malcolm WF. Long-term morbidities associated with vocal cord paralysis after surgical closure of a patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 2010; 30(6): 408-13[DOI][PubMed]
  • 13. Amoozgar H, Ghodstehrani M, Pishva N. Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. Pediatr Cardiol. 2010; 31(1): 40-3[DOI][PubMed]
  • 14. Timethy M, Hugh D. , Allen DJ, Driscoll RES. Physiology of the preterm and term infant. Moss and Adams' Heart Disease in Infants, Children, and Adolescents. 2008; : 440-1
  • 15. Gittenberger-de Groot AC. Persistent ductus arteriosus: most probably a primary congenital malformation. Br Heart J. 1977; 39(6): 610-8[PubMed]
  • 16. McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics. 1978; 62(5): 706-12[PubMed]
  • 17. Watanabe K, Tomita H, Ono Y, Yamada O, Kurosaki K, Echigo S. Intravenous indomethacin therapy in infants with a patent ductus arteriosus complicating other congenital heart defects. Circ J. 2003; 67(9): 750-2[PubMed]
  • 18. Takami T, Yoda H, Kawakami T, Yamamura H, Nakanishi T, Nakazawa M, et al. Usefulness of indomethacin for patent ductus arteriosus in full-term infants. Pediatr Cardiol. 2007; 28(1): 46-50[DOI][PubMed]
  • 19. Rudolph AM. Congenital Disease of The Heart. 2001; : 155-96
  • 20. Weiss H, Cooper B, Brook M, Schlueter M, Clyman R. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr. 1995; 127(3): 466-71[PubMed]
  • 21. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005; 164(3): 135-40[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments